| Year |
|---|
| Current Assets |
| Cash & Short Term Investments |
| Cash And Cash Equivalents |
| Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Non-Current Assets |
| Property, Plant & Equipment |
| Goodwill And Intangible Assets |
| Goodwill |
| Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Other Assets |
| Total Assets |
| Current Liabilities |
| Accounts Payable |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Total Non-Current Liabilities |
| Long-Term Debt |
| Deferred Revenue |
| Deferred Taxes Liabilities |
| Other Non Current liabilities |
| Total Liabilities |
| Other Liabilities |
| Stockholders Equity |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income/Loss |
| Other Shareholders Equity |
| Total Liabilities and Stockholders Equity |
Mankind Pharma Limited
MANKIND.NS
NSE
2350.5INR36.55 (1.58%)
MANKIND.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 80.12B | 67.35B |
| Net Income | 19.13B | 12.82B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | 0 | 0 |
| Retained Earnings | 99.19B | 80.12B |
| Other Distributions | 19.07B | 12.77B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 31.39B | 30.76B |
| Annual Depreciation | 3.98B | 3.26B |
| Capital Expenditure | -3.82B | -8.32B |
| Net PPE | 31.23B | 35.82B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 0 | -4.2M |
| Goodwill (Previous Year) | 200.23M | 204.42M |
| Goodwill | 200.23M | 200.23M |